News & Events

Press Releases

Salarius Pharmaceuticals to Present at Biotech Showcase 2020

Salarius Pharmaceuticals Receives FDA Fast Track Designation for Lead Drug Candidate, Seclidemstat, in Relapsed or Refractory Ewing Sarcoma

Phase 1/2 Clinical Study Now Underway; Salarius Targeting Key Safety and Efficacy Data Milestones in 2020

Salarius Pharmaceuticals to Present Trial-in-Progress Poster at Epigenetics Symposium: 15 Years of Lysine Demethylases: From Discovery to the Clinic

Salarius Pharmaceuticals Reports Three and Nine Month 2019 Financial Results

Events

38th Annual J.P. Morgan Healthcare Conference

Jan 13 - Jan 16

Listen to Webcast

Epigenetics Symposium: 15 Years of Lysine Demethylases: From Discovery to the Clinic

Dec 16 @ 8:30 am EST to 7pm EST

https://www.foxchase.org/events/epigenetics-symposium-15-years-lysine-demethylases-discovery-clinic

61st ASH Annual Meeting & Exposition

Dec 7 - Dec 10

Oppenheimer Oncology Summit: The Evolving Strategies in Targeted Drug Development

Oct 17

In the News

Reportable News

Salarius During the JP Morgan Week – Attend the Biotech Showcase Presentation or Join the Live Webcast

Proactive Investors

Salarius Pharmaceuticals CEO talks through recent achievements for its lead cancer drug candidate

Scrip Informa Pharma Intelligence

Scrip Asks…What Does 2020 Hold For Biopharma? Part 3: Policy And Regulation

Applied Clinical Trials

Emerging Biopharma Find Ways to Persevere Struggles

Salarius CEO, David Arthur discusses the future of the company with SNN Network

Salarius, Aspire Capital announce a $10.9M stock purchase agreement